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Metabolic reprogramming has been identified as an important driver of breast cancer 
(BC) metastatic spread, particularly through upregulation of the anaplerotic enzyme pyruvate 
carboxylase (PC). We hypothesize that loss of PC will sensitize BC cells to additional metabolic 
alterations, primarily the restriction of serine, glycine, and glutamine. PC inhibition was modeled 
in metM-WntLung BC cells in vitro with siPC and shPC constructs. Cell viability and migration 
assays were conducted following exogenous serine and glycine restriction or glutaminase 
inhibition. Serine and glycine restriction reduced cell proliferation and metastasis in scramble 
conditions and targeted many prognostic biomarkers of metastasis. Similar responses were 
observed with glutaminase inhibition; however, PC loss did not contribute to impaired growth or 
metastasis. Ongoing work will assess this response in vivo with a surgical tumor resection model. 
This study therefore highlights altered metabolic reprogramming, particularly through depletion 
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CHAPTER 1: INTRODUCTION 
Breast Cancer Prevalence and Mortality 
 Cancer is a worldwide public health concern with rapidly increasing incidence and 
mortality rates1. In 2018 alone, there were 18.1 million new reported cancer cases and 9.1 million 
cancer deaths. Among women, breast cancer (BC) is the most commonly diagnosed cancer and 
the second leading cause of cancer-related death in the United States2. Using gene expression 
techniques to evaluate the presence of estrogen and progesterone hormone receptors (HR), and 
human epidermal growth factor receptor 2 (HER2), BC tumors can be divided into four molecular 
subtypes: Luminal A (HR+HER2-), Luminal B (HR+HER2+), HER2-enriched (HR-HER2+), and 
Triple Negative BC (TNBC, HR-HER2-)3–5. Although Luminal A is the most common subtype, 
representing roughly 73% of all BC cases, TNBC has the lowest 5-year survival rate, and is 
associated with elevated rates of recurrence and metastasis compared with non-TNBC subtypes4–
8.   
The prognosis of BC subtypes is often informed by the tumor’s ability to metastasize, or 
disseminate from a localized, primary origin to nearby lymph nodes and distant organs. In BC, this 
metastatic spread most commonly occurs to the lungs, liver, bones, or brain, all of which present 
significant clinical challenges for BC treatment9,10. Strikingly, TNBC patients, who often develop 
early liver and lung metastases, may require specialized treatment approaches given the cancer’s 
high rate of resistance to conventional therapies7,11,12. Although advances in treatment and early 
mammographic detection reported between 1989 and 2017 prompted a 40% decline in overall BC 
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deaths, metastasis remains one of the largest contributors to BC mortality13. Importantly, patients 
with Stage I, localized BCs have a nearly 100% five-year survival rate, whereas patients with Stage 
IV, metastatic BCs have only a 27% five-year survival rate14. As there is no cure for metastatic 
BC, current treatment options must instead focus on managing recurrence and progression of the 
disease, highlighting the importance of research in this field. 
Obesity and Breast Cancer 
One established risk factor for many BC subtypes is obesity, an epidemic affecting over one-
third of the entire United States adult population15. Approximately 85,000 new cancer cases per year 
can be attributed to obesity, 9% of which are BC cases16. More specifically, obesity has been linked to 
an increased incidence of aggressive TNBCs, particularly in African American women17. Not only are 
obese women at a higher risk of developing BC, but they are more likely to have greater tumor burden 
at time of diagnosis and more disseminated recurrence following remission than nonobese women18–
21. Furthermore, studies suggest that obese patients are often less sensitive to chemotherapy treatment 
compared with nonobese patients22. BMI in the obese range ( ≥30kg/m2) is associated with a greater 
risk of mortality following BC diagnosis, with some studies indicating as much as a 3-fold increased 
risk compared with normal weight individuals23–26.   
On a cellular level, an influx of excess energy in the obese state is converted to triacylglycerol 
and stored in adipose tissue depots. Adipose tissue responds to the accumulation of triacylglycerol 
primarily through the growth of preexisting adipocytes, a process known as adipose hypertrophy27. 
This chronic positive energy balance and atypical expansion of adipocytes promotes adipocyte hypoxia 
and necrosis. While normal cells die under the stress of hypoxic and necrotic conditions, cancer cells 
can adapt to the nutrient stress by reprogramming their gene expression profiles28. Furthermore, 
adipocyte death promotes adipose tissue inflammation, driving some of the known phenotypes 
associated with obesity29.  
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This reprogramming provides a fitness advantage to cancer cells, increasing expression of 
epigenetic factors such as HIF-1𝛼 and HIF-2𝛼, which in turn activate cellular responses and drive cells 
into a dynamic process known as epithelial-to-mesenchymal transition (EMT)27,30–32. Cells that 
undergo EMT experience multiple molecular changes that enable them to transition from polarized, 
epithelial cells into mobile, mesenchymal cells33,34. These changes enhance the cell’s migratory 
capacity, stemness, invasiveness and resistance to apoptosis, which thereby contribute to cancer 
progression and metastasis34,35. Our lab has previously found obesity to drive EMT in mouse models 
of TNBC using MMTV-Wnt-1 BC cells33. Gene expression analyses of tumors from lean and obese 
mice in this model displayed significant upregulation of pro-tumorigenic pathways in obese-state 
tumors compared with lean, specifically those involved in regulating EMT. Additionally, serum 
isolated from obese mice stimulated greater invasive and migratory capabilities of TNBC cells in vitro 
than serum from lean mice33. The precise mechanisms underlying the link between obesity and BC 
metastasis, however, remain elusive. 
Metabolic Reprogramming 
Despite this gap in knowledge, metabolic reprogramming has been identified as a hallmark 
of both obesity and metastatic spread36–38. Unlike primary and localized cancer cells, metastasizing 
cancer cells experience additional environmental and genetic stressors while metastasizing, 
including increased oxidative stress, reduced oxygen and nutrient supply, and the sheer forces of 
detachment39,40. Disseminating cells must therefore acquire metabolic adaptations and adaptive 
stress response pathways to sustain their transformation and evade potent antioxidants. Increasing 
evidence suggests that these cells are enriched in factors that regulate mitochondrial respiration, 
oxidative phosphorylation, and biogenesis41,42.  
The metastatic cascade is composed of multiple steps, including invasion, survival in 
circulation, extravasation at the distant organ site, and colonization39. Metabolic phenotypes and 
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dependencies change as cancer cells progress through different stages of the metastatic cascade40. 
The invasion of disseminating cells into surrounding tissues is supported by increased expression 
of hexokinase and pyruvate kinase, enzymes involved in glycolysis and lactate production, 
respectively43.  In BC, increased flux through glycolysis generates metabolic by-products that 
activate signaling pathways to induce EMT44. Moreover, increased lactate production promotes 
BC progression by supporting cell motility and extracellular acidification44,45. Fatty acid 
metabolism is also altered to support the invasion of migratory cells, in part through the induction 
of transforming growth factor 𝛽 (TGF𝛽) and Wnt signaling44,46,47. In addition, elevated expression 
of fatty acid synthase (FASN) is known to support proliferation and EMT induction in many cancer 
subtypes, including BC48.  
Once a metastasizing cancer cell invades into surrounding tissues, it must then survive in 
circulation. Given the elevated ROS levels in circulation, disseminating tumor cells must increase 
their antioxidant defense to avoid anoikis, a type of cell death caused by detachment from the 
extracellular matrix49. One way cancer cells strengthen this defense is through NADPH production 
via the lactate-driven pentose phosphate pathway and conversion of pyruvate to oxaloacetate. 
NADPH generation contributes to the recycling of glutathione, a ROS scavenger50. ROS 
scavenging by glutathione not only reduces anoikis, but also increases the stemness of cancer cells 
which can in turn support metastasis formation44,51. Interestingly, genetic depletion of intracellular 
pyruvate in cultured BC cells decreases both NADPH and glutathione levels, thus reducing ROS 
scavenging capacity and elevating oxidative stress52. These observations therefore suggest that 
availability of lactate and pyruvate, in addition to other metabolic reprogramming, support a 
successful transition of tumor cells in circulation.  
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Cancer cells that survive circulation extravasate and migrate to a secondary organ where 
they then colonize and begin proliferating. Like the other stages of metastasis, cancer cells that 
undergo colonization and seeding exhibit metabolic plasticity53. These cells are exposed to 
different tropisms at their secondary site compare to their primary site and thus different levels and 
types of nutrients49. They must therefore rely on metabolic reprogramming for ATP production, 
survival, and proliferation49. Furthermore, recent data suggests that the metabolic profiles of cancer 
cells may differ based on the site to which they metastasize41,54,55. For example, BC-derived lung 
metastases use glucose to fuel both glycolysis and mitochondrial metabolism, whereas BC-derived 
liver metastases only rely on glycolysis for energy production54,56. Additionally, BC cells that 
colonize to the lungs require increased extracellular pyruvate, but not lactate for remodeling of the 
extracellular matrix57. Fatty acids have also been identified as important nutrients for ATP 
generation in colonization and seeding49. TNBC cells, in particular, require increased fatty acid 
oxidation for formation of secondary tumors compared with non-metastatic BC cells58. Taken 
together, each metabolic change experienced throughout the metastatic cascade provides cancer 
cells with the energy and substrates necessary to support growth, proliferation, and migration, as 
well as survival59.  
Obesity is another major contributor to altered metabolic programs. The increase in adipose 
tissue mass observed in obesity stimulates elevated levels of adipokines such as leptin and 
adiponectin, which are known regulators of metabolic homeostasis and energy balance60. 
Moreover, obesity causes significant transcriptomic changes in metabolic pathways including fatty 
acid metabolism and oxidative phosphorylation61. The overexpression of genes associated with 
fatty acid metabolism, as well as the increase in lipid accumulation, have been directly linked to 
invasive and migratory traits of cancer cells62,63. More specifically, obesity-derived changes in 
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fatty acid metabolism have been observed to elevate the seeding capacities of tumor cells at distant 
organs in several BC mouse models and are linked with poor prognosis in patients of various 
cancers64–66. By supplying ample metabolites and increasing supportive growth-factor signaling, 
the metabolic changes stimulated by obesity may directly promote metastatic spread67. Therefore, 
the metabolic needs of disseminating tumor cells is an important link between obesity and 
metastatic mechanisms.  
Pyruvate Carboxylase Mediated Anaplerosis 
One specific metabolic change observed in both obesity and metastatic disease is the 
upregulation of pyruvate carboxylase (PC). As a critical anaplerotic enzyme, PC catalyzes the 
carboxylation of pyruvate to oxaloacetate, thereby aiding in the regeneration of TCA cycle 
intermediates lost during cataplerotic pathways68. PC activity is regulated by various physiological 
conditions, including dietary alterations and genetic obesity69. Cell culture studies have identified 
a ~10-fold increase in PC mRNA and ~20-fold increase in PC enzyme synthesis in mature 
adipocytes compared with 3T3-L1 preadipocytes, indicating PC is important to adipocyte  
differentiation and thus potentially contributes to adipose biology in obesity70,71. PC is critical for 
both gluconeogenesis and lipogenesis, and therefore, high fat conditions have been shown to drive 
an increased flux of pyruvate through PC to meet metabolic needs72,73. Decreasing PC expression 
through a loss-of-function approach in rat models reduced both adiposity and plasma lipid 
concentrations in high-fat diet fed rats, and reduced body weight gain over time74.  
In addition, most proliferating cells, but particularly proliferating cancer cells, require 
sufficient TCA cycle intermediates for biomass production75. In BC cells, the anaplerotic entry of 
pyruvate into the TCA cycle via PC has been associated with invasive phenotypes and large tumor 
size49,76,77. Clinically, PC is commonly upregulated in human BC tissues, with the METABRIC 
   
 7 
patient dataset identifying elevated genomic copies of the enzyme in as many as 30% of patients 
with metastatic BC. High PC expression in these patients was associated with decreased survival 
rates78. Overexpression of PC has also been shown to increase proliferative, migratory, and 
invasive capabilities of TNBC cell lines in vitro76. Reducing expression of PC in these cell lines, 
however, demonstrated significant reduction in both viability and proliferation rates, suggesting 
the important role of this enzyme in BC survival and growth76,77. Subsequent in vivo evidence has 
demonstrated that PC is required for BC that has metastasized to the lungs, but is not necessary for 
primary tumor growth78. This study also assessed the rate of glycolysis and oxygen consumption 
in 4T1 BC cells and concluded that the metabolic plasticity of these TNBC cells was dependent 
on PC expression78.  
PHGDH-Mediated Synthesis of Serine and Glycine 
Whereas non-transformed cells with no migratory capabilities have low demands for the 
nonessential amino acids (NEAA) serine and glycine, many metastatic cancer subtypes depend on 
higher activation levels of intracellular serine and glycine synthesis via phosphoglycerate 
dehydrogenase (PHGDH) for proliferation and migration79. Many cancer cells consume sufficient 
exogenous serine and glycine for optimal growth; however, by utilizing de novo synthesis 
pathways in combination with dietary serine and glycine, cancer cells can enhance their 
macromolecule synthesis and neutralize high levels of oxidative stress80. Moreover, cells can adapt 
to extracellular serine starvation by activating de novo serine biosynthesis via PHGDH79. 
Surprisingly, exogenous serine and glycine uptake far exceeds the demands for one-carbon 
metabolism; however, when PHGDH is inhibited, supplementation with exogenous serine and 
glycine is insufficient to rescue one-carbon metabolism and nucleotide biosynthesis81. PHGDH-
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mediated serine and glycine biosynthesis must therefore be involved in both a complex but 
necessary mechanism driving downstream metabolites. 
 A rate limiting enzyme in serine biosynthesis, PHGDH first catalyzes the oxidation of 3-
phosphoglycerate to 3-phosphohydroxypyruvate82. The subsequent transamination reaction 
catalyzed by phosphoserine amino transferase (PSAT) converts 3-phosphohydroxypyruvate to 3-
phosphoserine. This reaction requires glutamate as a nitrogen donor and produces 𝛼-ketoglutarate 
to fuel the TCA cycle81. The depletion of glutamate can be compensated for by PC’s ability to 
increase TCA cycle intermediates, but may be impaired when PC is lost75. Finally, 
dephosphorylation of phosphoserine generates serine which can be further converted to glycine. 
Serine and glycine contribute to a number of important processes, including nucleotide and lipid 
synthesis, antioxidant defense via glutathione synthesis, and a supply of one-carbon units for folate 
and methylation cycles (see Figure 1)80,81.   
Interestingly, PHGDH is amplified in 70% of TNBCs and expression levels may be 
increased following activation of oncogenes such as KRAS and MYC82–84. In breast tumors, high 
expression of PHGDH is correlated with increased metastasis in mice85. These elevated levels are 
linked with shorter time to relapse, shorter survival times, higher tumor grades, and increased 
expression of proliferative markers in multiple BC subtypes, TNBC included86. Some recent data 
generated with small-molecule PHGDH inhibitors suggest that PHGDH activity may be required 
to support the proliferation and survival of cells in addition to tumor growth87,88. Additional work, 
however, is needed to understand whether high PHGDH expression plays a role in tumorigenesis 
or other steps of the metastatic cascade. Further depletion of PHGDH has shown potent and 
selective toxicity against lung cancer cells89. There is thus a compelling implication that PHGDH 
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may serve as a metabolic gatekeeper for macromolecule biosynthesis as well as serine-mediated 
nucleotide synthesis90.   
 Finally, glutamine serves as an important regulator of tumor metabolism, contributing to 
bioenergetics, antioxidant support, and macromolecule production. It also influences a number of 
signaling pathways and genes that contribute to tumor growth, including the ERK signaling 
pathway which is involved in proliferation, differentiation, and survival processes91,92. 
Importantly, glutamine can be converted to its downstream metabolite glutamate via the enzyme 
glutaminase (GLS), where it can then be used to replenish TCA cycle intermediates by generating 
𝛼-ketoglutarate. In fact, in cells overexpressing PHGDH, as much as half of all glutamate-derived 
𝛼-ketoglutarate comes from the PHGDH pathway itself90. Subsequently, glutamate’s role in 
generating TCA cycle intermediates also supports production of NADPH for glutathione 
synthesis91. The conversion of glutamine to glutamate via GLS, and subsequent downstream 
mechanisms, have been directly correlated with tumor growth rates in vivo. These rates can be 








































Figure 1. PC and PHGDH metabolic mechanisms. Conversion of glucose-derived pyruvate to 
oxaloacetate via pyruvate carboxylase (PC) replenishes TCA cycle intermediates and intracellular 
glutamate levels. De novo serine biosynthesis via phosphoglycerate dehydrogenase (PHGDH) and 
phosphoserine aminotransferase (PSAT1) provides one-carbon units for folate metabolism and can 
further be converted to glycine using the enzyme serine hydroxymethyltransferase (SHMT1&2). 
Downstream glutathione (GSH) synthesis inhibits reactive oxygen species (ROS). PK, pyruvate 
kinase; LDH, lactate dehydrogenase; PDH, pyruvate dehydrogenase.  
 
While PC and PHGDH separately exhibit strong roles in driving metastatic spread, their 
association with glutamate suggests an important interaction that, when disrupted, may impair 
metastasis. Given the impact of obesity on BC survival and progression, it is imperative to 
understand the role of these enzymes and how their relationship may alter downstream metabolic 
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Project Goals 
The goals of this project are as follows:  
Aim 1: Determine whether loss of PC sensitizes BC cells to loss of extracellular serine and glycine 
in vitro. 
 1a: Determine whether proliferation or migration of BC cells are altered in the presence or 
absence of extracellular serine and glycine concentrations following suppression of PC.  
 1b: Determine the transcriptional response to suppression of PC in the presence or absence 
of serine and glycine.  
Aim 2: Assess the role of PC loss in combination with reduced glutaminase activity on metastatic 



















CHAPTER 2: METHODS 
Parental Cell Lines Used 
Metastatic metM-WntLung BC cells were derived from lung metastases following serial 
transplantation of nonmetastatic M-Wnt cells  (claudin-low, TNBC) into the mammary fat pad of 
a SCID mouse95. These cells were maintained in growth media (RPMI, 11.1mM Glucose, 10% FBS, 
50IU/mL Penicillin/Streptomycin, 2mM L-glutamine, 10mM HEPES buffer) at 37°C and 5% CO2.  
PC Reverse siRNA Transfection 
10nM of ON-TARGETplus SMARTpool PCx siRNA (Dharmacon, Lafayette, CO) was 
used to silence the PC gene in metM-WntLung cells (siPC). 10𝜇M Ambion silencer negative control  
siRNA cat#4390843 (ThermoFisher Scientific, Waltham, MA) was used as a negative control 
(siScr). The siRNA transfection was optimized using 6𝜇L Lipofectamine3000-RNAimax per well 
(Invitrogen, Carlsbad, CA). Each siRNA and lipofectamine were diluted separately in 750𝜇𝐿 Opti-
MEM (Gibco) and incubated at room temperature for 5 min. The two solutions were then mixed 
and incubated for an additional 15 min. Each mixture was added to a resuspension of metM-
WntLung cells diluted in RPMI growth media. siScr and siPC cells were then seeded in 10cm dishes 
(1,000,000 cells per dish) to allow proper PC knockdown prior to experimentation. After 24 hours, 
siScr and siPC cells were trypsinized and re-seeded for experimental assays. RNA was isolated 
from each condition using the Omega E.Z.N.A HP Total RNA kit (BioTek, Winooski, VT), 
according to manufacturer instructions. cDNA was then synthesized using 2𝜇g RNA and a master 
mix of 200𝜇M dNTP, 50UI/𝜇L reverse transcriptase, 10xRT buffers, and 10xRT primers 
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(ThermoFisher Scientific, Waltham, MA), then incubated in a thermocycler using manufacturers 
protocol. cDNA was combined with Universal SYBR Green super-mix (Biorad, Hercules, CA), 
Pcx, Phgdh, Rpl4, Rplp0, and Actb primer sequences obtained from a PrimerBank and purchased 
from IDT (IDT, Coralville, IA)96. A qPCR assay was run to verify PC expression.   
Doxycycline-induced Lentiviral shRNA Construct Generation 
SMARTvector plasmids encoding doxycycline inducible PC shRNA (shPC) 
(Dharmacon, Lafayette, CO) were a kind gift from Dr. Dorothy Teegarden at Purdue University 
(West Lafayette, IN). SMARTvector Inducible Non-targeting shRNA (shScr) was used as a 
control. These plasmids, along with the psPAX2 packaging construct and the PMD2.G viral 
envelope construct (Addgene, Watertown, MA), were co-transfected into HEK293T cells using a 
lipofectamine transfection reagent. After 24 hours, the media was collected from the HEK293T 
cells with a Luer-lock syringe, filtered through a 0.45-micron filter, and added directly to our 
plated metM-WntLung cells. Polybrene was then added to the media at a concentration of 1:1000 
to increase the efficiency of viral infection. This process was repeated once more at 48 hours 
post-transduction to obtain our shScr and shPC metM-WntLung cells.  
shPC Cell Sorting and Cloning 
After 48 hours of viral infection, shPC metM-WntLung cells were allowed to recover for 
24 hours in RPMI growth media. Successfully transduced shPC cells were then selected for with 
puromycin treatment (5𝜇g/mL) for 72 hours or until at least 80% of non-transduced cells died. 
Puromycin was removed and remaining cells began treatment with doxycycline (1𝜇g/mL) in 
RPMI growth media to induce shRNA knockdown and corresponding GFP expression. GFP 
expression was monitored after 48 hours of doxycycline treatment via a fluorescent microscope. 
To optimize the longevity and stability of the infected metM-WntLung cells, these cells were 
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sorted with a FACS Aria II under BSL-2 conditions and the highest GFP-expressing cells were 
selected (UNC Flow Cytometry core, Chapel Hill, NC).   
Media Conditions 
RPMI-1640 #R9660 media without glucose, glycine, or serine with 10% FBS, 10mM 
HEPES buffer, 11.1mM D-glucose was used for serine and glycine restricted media conditions 
(Teknova, Hollister, CA). This media, supplemented with standard RPMI concentrations of 
285𝜇M serine, and 133 𝜇M glycine, was used as the control media against serine and glycine 
restricted conditions. For BPTES conditions, normal growth media (RPMI, 11.1mM glucose, 10% 
FBS, 2mM L-glutamine, 10mM HEPES buffer) was supplemented with 4𝜇M BPTES (Med Chem 
Express, Monmouth Junction, NJ). Normal growth media without BPTES served as a control 
condition. 1𝜇g/mL of doxycycline was added to all shScr and shPC media conditions during 
seeding and media treatment timepoints. 
MTT Cell Viability Assay 
MTT assays were conducted using siScr, siPC, shScr, and shPC metM-WntLung cell lines 
under experimental conditions (± serine and glycine, or ± BPTES). All cells were seeded into a 
96 well plate (5,000 cells per well) in normal RPMI growth media and incubated for 24 hours at 37ºC 
and 5% CO2 (shScr and shPC cells were seeded with doxycycline (1𝜇g/mL)). Following incubation, 
RPMI media was replaced with 100μL of each respective experimental condition for an additional 24 
hours (media conditions for shScr and shPC cells were supplemented with doxycycline (1𝜇g/mL)). 
Media was then aspirated and the cells were stained with 100𝜇L of diluted MTT solution (5mg/mL of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and 10% cell culture media) for an 
additional 90 minutes, covered, and incubated at 37°C and 5% CO2. The MTT reagent was removed, 
100uL of dimethylsulfoxide (DMSO) was added, and the plates were shaken for 15 minutes. Cell 
viability was recorded using a Cytation 3 Cell Imaging Reader (BioTek, Winooski, VT) at 595 and 
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690nm. The absorbances (595-690nm) of each treatment group were calculated relative to the 
absorbance (595-690nm) of the scramble control for cell viability.  
Wound Healing Assay 
Cell migration chambers (Ibidi, Fitchburg, WI) were placed in each well of a 12 well plate. 
siScr and siPC metM-WntLung cells with prior PC knockdown were seeded (35,000 cells per 
chamber side) in normal RPMI growth media and incubated at 37°C and 5% CO2 for 24 hours. 
shScr and shPC metM-WntLung cells were seeded (25,000 cells per chamber side) in normal RPMI 
growth media supplemented with doxycycline (1𝜇g/mL to induce PC knockdown and incubated 
at 37°C and 5% CO2 for 24 hours. After cell adherence in all groups, the chambers were lifted 
from the wells and media was aspirated. 1mL of each media condition (± serine and glycine, or ± 
BPTES) was added dropwise to each well and imaged immediately at the start of serine and glycine 
restriction and 24h later using a EVOS FL Auto 2 Imaging System (ThermoFisher Scientific, 
Waltham, MA). Percent closure was calculated using the MRI Wound Healing Plugin on ImageJ 
software. 
Western Blotting 
 To confirm PC knockdown, shPC metM-WntLung cells were seeded into 10cm dishes in 
RPMI growth media with doxycycline (1𝜇g/mL) for 48 hours (1,800,000 cells/dish) to reach 70% 
confluence. Cells were gently washed with PBS and whole cell lysates were generated using RIPA 
lysis buffer (Sigma Aldrich, St. Louis, MO), HALT protease inhibitor cocktail (Sigma Aldrich, St. 
Louis, MO), and phosphatase inhibitors (1mM Sodium Pyrophosphate (SPP), 2mM Sodium 
Orthovanadate (NA3VO4), 250µM 𝛽-Glycerophosphate (BGP)). Cells were scraped and incubated 
on ice for 20 minutes before centrifugation for 15 minutes at 4°C. The protein-containing 
supernatant was then collected and protein concentrations were determined via a Bradford assay. 
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Protein lysates were denatured for 5 minutes at 95°C in a loading buffer (Biorad, Hercules, CA) 
containing 5% 𝛽-mercaptoethanol (BME). Following denaturation, protein samples were loaded 
onto a gel and separated via SDS-PAGE then transferred to a membrane for immunoblotting.  
Membranes were blocked in Tris-buffered saline containing 0.1% Tween 20 (TBST) and 5% non-
fat powdered milk for one hour at room temperature. The membranes were then incubated at 4°C 
with a 1:1,000 dilution of a PC primary antibody (anti-PCb cat#ab126707 Abcam, Cambridge, 
UK), or a 1:1,000 dilution of a PHGDH primary antibody (anti-PHGDH cat#66350 Cell Signaling 
Technologies, Danvers MA) in TBST with 5% non-fat powdered milk overnight. Gels were 
washed with TBST 3 times for 5 minutes each, then treated with a 1:10,000 dilution of IRDye 
800CW secondary anti-rabbit antibody (LiCor, Lincoln, NE) for one hour at room temperature. A 
1:5000 dilution of 𝛽-actin was used as a loading control in combination with a 1:10,000 dilution 
of  IRDye 680RD anti-mouse secondary antibody (LiCor, Lincoln, NE). Gels were read using an 
Odyssey infrared imaging system (LiCor, Lincoln, NE) at 700 and 800nm, and images were 
quantified using the Fiji distribution of ImageJ software97.  
Gene Expression Analysis 
Isolated RNA from the siSCR metM-WntLung and siPC metM-WntLung (± serine and 
glycine) cells in triplicate were diluted to a concentration of 83.3 ng/𝜇L and processed for 
microarray gene expression analysis using Clariom S HT arrays (Affymetrix, Santa Clara, CA). 
Sample gene expression levels were generated using TAC 4.0 software correcting for batch effects 
(Affymetrix, Santa Clara, CA). Gene Set Enrichment Analysis (GSEA) was performed on sample-
level data using default parameters of 1000 gene set permutations98,99.  
Statistical Analysis 
 Data was analyzed using GraphPad Prism 9 software (GraphPad Software inc., San Diego, 
CA). Statistical analysis was determined using a one-way analysis of variance (ANOVA) with 
   
 17 
Tukey’s post-hoc multiple comparisons test.  Due to large variances induced by the serine and 
glycine restriction, a two-way ANOVA was conducted to determine both the PC and serine and 
glycine interactions in shPC cells. Any p-values less than 0.05 after correction for multiple 
hypothesis testing were considered significant. Hallmark gene sets identified in GSEA analysis 
























CHAPTER 3: SERINE AND GLYCINE RESTRICTION INCREASES PC ACTIVITY 
AND DRIVES MIGRATORY SIGNALING MECHANISMS 
 
Background 
Serine and Glycine Restriction 
 As amino acids provide essential carbon and nitrogen sources, it comes as no surprise 
that cancer cells can utilize amino acid metabolism for up to 58% of their total energy 
expenditure to support protein and nucleotide synthesis100. Cumulative research findings suggest 
that amino acid restriction may play a crucial role in cancer interventions100. Limiting the supply 
of these critical nutrients, particularly through serine and glycine starvation, show potent 
toxicity83,101. Glycine, in particular, is an integral component of glutathione for redox balance, 
fuels heme biosynthesis, and sustains oxidative phosphorylation102,103. Both glycine and the 
expression levels of enzymes associated in the serine and glycine biosynthesis pathway, 
specifically SHMT, correlate with high proliferation rates in cancer cells101.   
Although serine and glycine can be interconverted, cancer cells demonstrate a preference 
for serine over glycine in support of growth mechanisms. More specifically, cancer cells 
selectively consume exogenous serine to synthesize intracellular glycine for subsequent one-
carbon metabolism. Uptake of exogenous glycine, however, is insufficient in supporting one-
carbon metabolism and nucleotide biosynthesis when serine is absent104. Furthermore, serine 
starvation has been shown to induce the tumor suppressor protein p53 in cells, a known driver of 
cell survival under metabolic stress105. In cancers, the p53 gene is frequently mutated, thereby 
enabling tumorigenesis and cancer progression106. Typically, serine starvation triggers activation 
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of the serine biosynthesis pathways, including PHGDH, and suppresses aerobic glycolysis to 
support an increased flux through the TCA cycle107. p53-deficient tumors, however, are unable to 
trigger these pathways and therefore become more sensitive to serine depletion, experiencing 
high levels of oxidative stress, and severely impaired proliferation105. Strikingly, 72% of all 
TNBCs have p53 mutations, an alteration that establishes their aggressive and metastatic 
phenotypes and poor patient outcomes108. Dietary serine and glycine restriction may therefore 
present an important therapeutic approach for targeting the carcinogenesis and disease 
progression of these cancers. 
 When serine is abundant, it binds the enzyme PKM2, the M2 isoform of pyruvate kinase 
(PK), increasing the rate of aerobic glycolysis and allowing for additional consumption of 
glucose109. Upon serine deprivation, PKM2 activity is reduced and glycolytic metabolites are 
diverted to serine biosynthetic pathways to increase intracellular serine concentrations and 
sustain cell proliferation102. In BC models, serine may support pyruvate production during PKM2 
knockdown, suggesting a reliance of BC cells on PHGDH-derived serine for cell growth89,90. 
This further implies that serine supports aerobic glycolysis and lactate production for cancer cell 
growth and survival, but when lost, may significantly impair these processes. Interestingly, this 
reliance upon serine favors endogenous levels of the amino acid, as seen when PHGDH 
suppression inhibits cancer cell proliferation despite high concentrations of exogenous serine102. 
Although dietary serine restriction slows tumor growth and increases survival in mouse models, 
studies suggest that de novo serine biosynthesis must also be targeted in combination for 
improved therapeutic efficacy79,83,110. Restriction of extracellular serine and glycine via dietary 
interventions, in tandem with intracellular inhibition of de novo serine and glycine biosynthesis 
via PHGDH reduction, may thus provide the most robust therapeutic approach.  
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 While the critical role for PC and PHGDH-mediated serine and glycine biosynthesis are 
independently supported by extensive research in cancer progression and metastasis, the link 
between these pathways is poorly understood. PC and PHGDH both determine the contribution 
of glucose-derived carbon to various branches of TCA and nucleotide metabolism. While 
inhibition of PHGDH reduces flux of one-carbon groups into nucleotide metabolism, suppression 
of TCA metabolic flux is more profound. Indeed, inhibition of PHGDH suppresses PC-mediated 
pyruvate-to-oxaloacetate conversion81. This work highlights the emerging link between PC and 
PHGDH-mediated serine and glycine biosynthesis, however, further investigation is required. 
Some studies have also established that suppression of PHGDH in MDA-MB-231 BC cells not 
only lowers serine biosynthesis and decreases cell proliferation rates, but also reduces 𝛼-
ketoglutarate levels77. These findings mirror the impact of PC knockdown on serine and 𝛼-
ketoglutarate concentrations in the same MDA-MB-231 cells, yet the relationship between the 
two metabolic pathways has not been deeply investigated77,111. We therefore developed two 
metM-WntLung cell lines with suppressed PC, labeled siPC and shPC, and conducted in vitro 
experimental assays under serine and glycine restricted conditions to test the hypothesis that loss 
of PC sensitizes BC cells to loss of extracellular serine and glycine. 
Signaling Mechanisms 
Previous studies have identified numerous Hallmark gene sets, or genes coordinately 
altered in broad biological processes and signaling pathways, upregulated in metastatic BC 
subtypes. Some of the most notable gene sets and pathways known to drive metastasizing tumors 
include EMT signaling, glucose metabolic pathways, growth factor pathways, and sex-hormone 
pathways112. There is also a strong, but conflicting relationship between cancer stem cells with 
high tumorigenic capacities and the innate interferon signaling pathways105. For example, 
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interferon-I is both pro-tumorigenic and anti-tumorigenic. In ovarian cancer cells, interferon-𝛼, a 
subtype of interferon-I, gene therapy exhibits anti-tumor effects and increases survival rates114. In 
MCF-7 BC cells, however, activation of the interferon-I pathway results in an increased expression 
of stem-like markers, thereby driving progression and migration of BC cells115. Additionally, 
interferon-I is known to activate other non-canonical signaling pathways including MAPK, PI3-K 
and NF-𝜅B which are commonly involved in carcinogenesis116–118. There is also evidence to 
suggest that some of these metastasis-inducing signaling pathways may drive increased PC 
expression. The EMT pathway, in particular, is one such pathway induced by Wnt and Snai1 
pathways119. Studies have shown that stimulation of MCF-7 BC cells with Wnt ligands or 
increased Snail expression show drastic increases in PC expression, therefore linking PC 
expression and EMT signaling120. Increases in Wnt, 𝛽-catenin, and Snail signaling are known to 
increase glucose consumption and lactate production, thereby regulating cancer progression120,121. 
Furthermore, a more recent paper identified that PC knockdown inhibits the Wnt, 𝛽-catenin, and 
Snail signaling pathway to suppress BC growth and metastasis122.  
Results 
Restriction of serine and glycine increased PC and PHGDH expression in control conditions 
 To validate PC knockdown in each of our metM-WntLung cell lines, RNA isolation, cDNA 
synthesis, and qPCR were performed. siScr, siPC, shScr, and shPC cells were first seeded for 24 
hours, then treated in the presence or absence of serine and glycine supplemented media (± 285𝜇M 
serine and 133 𝜇M glycine) for 24 hours. shScr and shPC cells were additionally seeded and treated 
with 1𝜇g/mL of doxycycline to stimulate PC suppression. Following qPCR analysis, we identified 
successful PC knockdown in our siPC metM-WntLung cells compared to siScr control under normal 
serine and glycine concentrations (Fig. 2A p=0.0120). Serine and glycine restriction, however, 
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significantly increased PC expression in siScr cells, while siPC remained unchanged (Fig. 2A 
p=0.0053). These results were replicated in our shScr and shPC metM-WntLung cell lines. Relative 
mRNA expression of PC was reduced in shPC cells compared to shScr control under normal serine 
and glycine conditions found in commercial media when assessed using a 2-way ANOVA to 
validate PC knockdown separately from serine and glycine interactions (Fig. 2B p=0.0090). Like 
the siScr and siPC cells, serine and glycine restriction drove an increase in PC expression for shScr 
cells, but not shPC cells (Fig. 2B shScr -ser/gly p<0.0001). This data indicates that restriction of 
extracellular serine and glycine may drive an increased enzymatic need for PC support of 
intracellular biosynthetic pathways. When PC is lost, however, there is insufficient PC expression 
to support this need.  Alternatively, these findings may indicate regulation of PC expression by 
serine and glycine availability.  
Relative mRNA expression of PHGDH was also assessed in all cell lines following 
treatment with or without serine and glycine supplementation (± 285𝜇M serine and 133 𝜇M 
glycine) for 24 hours. Following serine and glycine restriction, PHGDH expression levels were 
significantly increased in both siScr (p=0.0144) and siPC (p=0.0211) conditions (Fig. 2C). shScr 
cells also experienced an increase in relative PHGDH expression following serine and glycine 
restriction (p=0.0200), but no difference was observed with PC suppression in the shPC cells (Fig. 
2D). Similar to the analysis of PC expression, this data indicates that serine and glycine restriction 
may increase the dependence for de novo serine and glycine biosynthesis, in part via PHGDH 
activity, independent of PC, to support BC survival mechanisms.  
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Figure 2: Serine and glycine restriction increased PC and PHGDH mRNA expression in siScr 
and shScr metM-WntLung cells. Relative mRNA expression of PC was assessed following the 
incubation of siScr and siPC metM-WntLung cells (A) and shScr and shPC metM-WntLung cells (B) 
in the presence (+ser/gly) or absence (-ser/gly) of 285𝜇M serine and 133 𝜇M glycine for 24 hours. 
Relative mRNA expression of PHGDH was assessed following the incubation of siScr and siPC 
cells (C) and shScr and shPC cells (D) in the presence (+ser/gly) or absence (-ser/gly) of 285𝜇M 
serine and 133 𝜇M glycine for 24 hours. Data are the mean of 5 biological replicates and error bars 
represent s.e.m. Letters denote significant comparisons between conditions. 
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To confirm the in vitro effects of PC loss on PC and PHGDH enzymatic activity seen in 
Figure 2, a Western blot was performed. Cell lysates were obtained from shScr and shPC cells 
following 48 hours of seeding with 1𝜇g/mL doxycycline and no additional treatment, then 
probed for PC and PHGDH proteins via Western Immunoblotting. Protein levels of PC and 
PHGDH were examined and quantified against 𝛽-actin using the Fiji distribution of ImageJ 
software. The Western was conducted without further optimization and thus the PC protein 
levels in the shScr and shPC cell lines were close to the limit of detection (Fig. 3A). Additional 
replicates and optimization are necessary to make claims about the change in protein levels 
observed between the two cell lines (Fig. 3C).  PHGDH protein levels, however, were robustly 
detected by the antibody (Fig. 3B). The fold change of PHGDH observed in shPC cells was not 






























       
 
 
                      
 
 
                                        
 
 
Figure 3. Abundance of PHGDH proteins were unchanged in shPC cells compared to control. 
shScr and shPC metM-WntLung cells were treated with normal RPMI growth media supplemented 
with 1𝜇g/mL of doxycycline for 48 hours. Protein lysates were collected and relative abundance 
of PC (A) and PHGDH (B) normalized to 𝛽-actin was assessed via western blotting techniques. 
Fold change of PC (C) and PHGDH (D) in shPC cells was compared to shScr control cells. Data 
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Loss of PC did not affect cell viability under serine and glycine restricted conditions 
 Having confirmed the successful reduction of PC in our siPC and shPC cells, as well as the 
effect of serine and glycine restriction on PC and PHGDH expression, we next assessed the 
restriction of extracellular serine and glycine on cell growth and viability. siScr, siPC, shScr, and 
shPC cells were seeded for 24 hours, then treated with or without serine and glycine (±285𝜇M 
serine and 133 𝜇M glycine) for an additional 24 hours. Cell viability was measured using an MTT 
assay to quantify the concentration of metabolically active cells in each treatment condition. 
Following 24 hours of serine and glycine restriction, siScr cells exhibited a significant decrease in 
the abundance of viable cells compared to siScr cells under normal serine and glycine 
concentrations (Fig. 4A p=0.0467). All other conditions, including the siPC cells, were not 
different. No cell viability differences were observed across conditions in either shScr or shPC 
cells, illustrating an important distinction in growth and reactivity between the siRNA and shRNA 
constructs (Fig. 4B). Taken together, this cell viability data indicates a potential growth inhibition 
effect of extracellular serine and glycine restriction on siScr cells, but not shScr cells. This 
response, however, was not replicated in siPC cells, suggesting that cell growth and proliferation 
was not impacted by loss of PC in these BC cells. Furthermore, loss of PC did not sensitize BC 
cells to serine and glycine restriction in this model.  
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Figure 4: Serine and glycine withdrawal reduced cell viability of siScr metM-WntLung cells. 
siScr and siPC metM-WntLung cells (A), and shScr and shPC metM-WntLung cells (B) were treated 
in the presence (+ser/gly) or absence (-ser/gly) of 285𝜇M serine and 133 𝜇M glycine for 24 hours 
and cell viability was assessed using an MTT assay. Data are the mean of 4 (A) and 5 (B) biological 
replicates and error bars represent s.e.m. Letters denote significant comparisons between 
conditions. 
 
Serine and glycine withdrawal reduced cell migration in cells with reduced PC expression  
 In addition to cell viability and growth inhibition, cell migration following serine and 
glycine restriction was also analyzed. siScr, siPC, shScr, and shPC cells were seeded in migration 
chambers to create a distinct cell wall. After 24 hours, the chambers were removed and the cells 
were treated with or without serine and glycine (±285𝜇M serine and 133 𝜇M glycine) for an 
additional 24 hours. Pictures were taken at the start of serine and glycine restriction and 24h later, 
and the percent wound closure was quantified using ImageJ software. Interestingly, neither loss of 
PC nor restriction of serine and glycine decreased the migration of siScr and siPC cells (Fig. 5A). 
The only notable decrease was observed between siPC cells under serine and glycine restricted 
conditions compared to siPC under normal conditions (p=0.0298). The shPC cells, on the other 
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hand, demonstrated a significant reduction in migratory capacity following serine and glycine 
restriction compared to control (Fig. 5B p=0.0023). Although these results are inconsistent across 
siRNA and  shRNA constructs, the reduction in migration observed in the shPC cells may suggest 
that loss of PC, in combination with extracellular serine and glycine restriction, has the greatest 
impact on reducing migration of the metM-WntLung cells in contrast to PC loss or amino acid 
restriction alone.  
 
           
 
Figure 5: Serine and glycine restriction reduced migratory capacity of shPC metM-WntLung 
cells. siScr and siPC metM-WntLung cells (A) and shScr and shPC metM-WntLung cells (B) were 
treated in the presence (+ser/gly) or absence (-ser/gly) of 285𝜇M serine and 133 𝜇M glycine for 
24 hours following seeding in migration chambers. Percent wound closure of each cell wall was 
imaged and quantified using the ImageJ MRI wound healing plugin. Data are the mean of 3 (A) 
and 4 (B) biological replicates and error bars represent s.e.m. Letters denote significant 
comparisons between conditions. 
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Restriction of serine and glycine impacted expression of hallmark metastatic gene sets                        
RNA was isolated from siScr and siPC cells following treatment with or without serine and 
glycine (±285𝜇M serine and 133 𝜇M glycine). RNA was then processed using the Clariom S HT 
microarray and Gene Set Enrichment Analysis (GSEA) to analyze expression of Hallmark gene 
sets driving the serine and glycine and PC effects observed in vitro. GSEA analysis identified 15 
hallmark gene sets with significant FDRq values, all 15 of which were upregulated in normal serine 
and glycine conditions (siScr+SG and siPC+SG) compared to restricted conditions (siSCR-SG and 
siPC-SG) (Fig. 6A, -log10FDRq>1.30). 14 of the 15 gene sets were altered in siPC cells, while 
only 5 were altered in siScr cells, pointing to the heightened sensitivity of siPC cells to serine and 
glycine manipulation. In all but one case, the gene sets identified between siScr and siPC cells 
overlapped. These 15 total gene sets included multiple Hallmark pathways known to drive tumor 
progression and metastasis, therefore suggesting that serine and glycine play a supportive role in 
these signaling pathways, and subsequent restriction may reduce these pro-tumorigenic effects. No 
significantly altered hallmark gene sets were identified in either the PC effect, comparing siPC+SG 
to siScr+SG nor in the comparison of siPC-SG to siScr+SG (Fig 6B,C). These results indicate that 
the proliferative and migratory responses observed in vitro may be largely driven by serine and 
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Figure 6: Hallmark gene sets identified via GSEA. RNA was isolated from siScr and SiPC 
metM-WntLung cells and processed for microarray gene expression analysis using Clariom S HT 
arrays and GSEA techniques. A serine and glycine effect comparing siScr+SG (pos) vs siScr-SG 
(neg), and siPC+SG (pos) vs siPC-SG (neg) identified 15 significantly enriched hallmark gene sets 
(A). Comparisons of siPC+SG (pos) vs siScr+SG (neg) (B) and siPC-SG (pos) vs siScr+SG (neg) 
(C) were also made. Color denotes comparison, NES indicates in which group a hallmark was 
enriched, size indicates -log10FDRq.  
 
Discussion 
In this study, two different metM-WntLung BC cell lines, labeled siPC and shPC, were 
generated via reverse siRNA transfection and lentiviral shRNA transduction, respectively, to 
model PC knockdown in vitro. These cells lines were treated under normal experimental 
conditions, and serine and glycine restricted conditions to test the hypothesis that loss of PC 
sensitizes BC cells to loss of extracellular serine and glycine. Our qPCR analysis revealed that PC 
expression levels were increased in siScr and shScr control cells when serine and glycine are 
restricted from cell culture media. This increase in PC expression indicates a shift from 
extracellular serine and glycine-driven growth mechanisms toward intracellular growth 
mechanisms for tumor homeostasis and survival. When serine and glycine are no longer present 
exogenously, cancer cells must metabolically adapt to support the demands of proliferation123. One 
way in which cancer cells exhibit metabolic plasticity is by driving an increased flux through the 
TCA cycle for energy production. PC expression may therefore be increased to sustain this TCA 
cycle intermediate generation, as seen in Figure 2. These results are consistent with the work of 
Maddocks et. al., who demonstrated an increase in the TCA cycle intermediate citrate following 
serine and glycine restriction in a colorectal carcinoma model105.  Subsequent work by Reid et. al., 
illustrate a similar finding with increased PC-mediated flux from pyruvate to oxaloacetate 
following PHGDH inhibition81. Interestingly PC expression levels in our siPC and shPC cells 
under restricted conditions were not significantly different than expression levels in the control 
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cells, suggesting that, despite PC knockdown and amino acid restriction, cancer cells can still 
metabolically adapt to support biosynthetic pathways, partially through boosting TCA cycle 
intermediates and anaplerotic enzymes.  
This phenomenon may be better explained by the increase in PHGDH levels also observed 
during extracellular serine and glycine restriction. Restriction of serine and glycine demonstrated 
a significant increase in the expression of PHGDH in siScr, siPC, and shScr compared to control 
conditions. This increase indicates that BC cells metabolically adapt under nutrient poor 
conditions, specifically inducing a shift toward de novo serine and glycine biosynthesis following 
loss of exogenous serine and glycine. As studies have previously highlighted, many cancer cells 
depend on intracellular serine and glycine biosynthesis for one-carbon metabolism, even in the 
presence of abundant extracellular levels124,125. Thus, when exogenous serine and glycine are 
limited, there may be a greater demand for de novo biosynthesis. Furthermore, the increase in 
PHGDH observed in siPC cells under restricted conditions may suggest the importance of 𝛼-
ketoglutarate in driving this mechanism. Surprisingly, the serine biosynthesis pathway contributes 
to approximately 50% of the total anaplerotic flux of glutamine and 𝛼-ketoglutarate into the TCA 
cycle in many BCs86. Given that PC also supports anaplerotic flux of carbon into the TCA cycle 
as oxaloacetate, cancer cells may rely more heavily on the transamination reaction in the serine 
biosynthesis pathway for 𝛼-ketoglutarate production when PC is lost. An increase in PHGDH 
expression would therefore support the hypothesis that loss of PC stimulates a metabolic shift 
toward the de novo serine biosynthesis pathway for 𝛼-ketoglutarate generation and nucleotide 
synthesis.  
Assessment of shScr and shPC protein levels was performed using a Western Immunoblot. 
Unfortunately, the Western was conducted without extensive optimization and the PC protein 
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levels were close to the limits of detection for the antibody. An increase in the quantity of protein 
loaded onto these gels may provide more robust results in the future. Additionally, no differences 
were observed in PHGDH protein levels in shPC cells compared to shScr cells, which is congruent 
with the enzymatic expression of PHGDH in these cells. Nevertheless, subsequent replicates and 
optimization of this Western Immunoblot must be completed to make more accurate conclusions 
about this data. 
Following the confirmation of PC knockdown and enzymatic activity in our siRNA and 
shRNA metM-WntLung constructs, we next performed MTT assays to assess cell viability and 
growth in the presence or absence of serine and glycine. Restricting serine and glycine 
demonstrated an effective reduction of cell viability in our siScr cells; however, no change was 
observed in any of the other cell lines or conditions. The reduction observed in the siScr cells is in 
agreement with studies that successfully reduced tumor cell proliferation rates after restricting 
dietary serine and glycine83,105. In one study, mice demonstrated a decrease in tumor volume and 
cell count after only 6 days on a serine and glycine restricted diet. The authors suggested that this 
may be in part due to loss of the tumor suppressor gene p53, thereby increasing the tumor’s 
vulnerability to serine and glycine starvation105. It has also been confirmed that loss or suppression 
of PC lowers the viability and proliferative capabilities of BC cells, as there is a downstream 
decrease in major metabolic metabolites required for BC growth77. For example, suppression of 
PC expression in the highly metastasizing MDA-MB-231 BC cells, reduces proliferation, 
migration, and invasion ability76. Our analysis, however, did not exhibit a reduction in proliferation 
rates in either siPC or shPC cells.  One possible explanation for these results is that PHGDH and 
de novo serine biosynthesis may be able to fully support nucleotide synthesis, energy production, 
and subsequent cancer cell proliferation when PC is lost126.  These findings may also be partially 
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attributable to incomplete PC suppression in our transfection and transduction methods. 
Considering the 48 hour timeframe for MTT cell viability assays, it is possible that the initial loss 
of PC was dampened over time. These results may also be caused by the natural ability of cancer 
cells to increase PC expression under nutrient stress, as seen in our qPCR data, to support survival, 
which would in turn support growth rather than inhibition. Additional replicates and optimization 
must be conducted to achieve optimal PC suppression in these cell lines.  
We further investigated the role of both PC suppression and extracellular serine and glycine 
restriction on BC metastatic spread using a migration assay. Here we demonstrated that serine and 
glycine restriction had a significant impact on reducing the migration of both our siScr and siPC 
cells. Limited research has been conducted on the direct link between dietary serine and glycine 
restriction and BC metastatic spread; however, other important non-essential amino acids, such as 
asparagine, are important in driving metastatic spread of BC models. More specifically, dietary 
asparagine restriction has been shown to reduce metastasis without affecting growth of the primary 
tumor, suggesting that this amino acid is crucial to the metastatic cascade, but not primary tumor 
survival127. A similar relationship between dietary serine and glycine and BC metastasis may 
therefore exist. Interestingly, PC facilitates dissemination from primary BC tumors to the lungs, 
but does not appear to be critical for the primary tumor itself. Further suppression of PC decreased 
pulmonary metastasis, but did not directly affect the primary tumor growth78. Contrary to the 
literature connecting PC suppression to reduced migration and metastasis, however, loss of PC in 
our siRNA construct did not reduce the migratory capacity of our cells122. These results may be 
subject to the same limitations experienced with the cell viability assays given the 48 hour 
timeframe for experimentation and ability for the serine biosynthesis pathway to support cancer 
cell survival and proliferation. Interestingly, shPC cells with restricted serine and glycine 
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concentrations exhibited a significant reduction in migration that was not observed in the shScr 
cells. While this response may be largely due to the effect of serine and glycine restriction on the 
spread of BC cells, the lack of change in shScr cells under the same condition indicates a possible 
inhibitory role of PC suppression on metastatic spread. The variation in results between siRNA 
and shRNA constructs, however, presents a significant limitation to this study. Further 
optimization of siRNA and shRNA constructs may provide more consistent and robust results. 
Subsequent analysis of enriched Hallmark gene sets in siScr and siPC cells under varying 
serine and glycine conditions was evaluated to identify mechanistic biomarkers driving the 
responses observed in vitro. Comparisons were made between siScr cells and siPC cells with or 
without serine and glycine as to determine the effect of serine and glycine on the differences 
observed in vitro. Additional comparisons were made to assess the effect of PC on the previous 
results. Of these comparisons, only the serine and glycine effect demonstrated significantly 
altered gene sets with a -log10FDRq value greater than 1.30. This comparison supports our cell 
viability and migration data where serine and glycine restriction were the main drivers of cell 
proliferation and spread. The insignificant alterations in gene sets highlighted in the PC effect 
concurs with our data suggesting that loss of PC is insufficient to change proliferation or 
migration rates of our BC cells.  
It has been well established that the EMT pathway, and its underlying molecular 
mechanisms, are critical for normal developmental processes, but also for cancer progression and 
migration. Importantly, studies have also identified the EMT pathway as a specific driver of BC 
invasiveness and metastasis128,129. Our GSEA analysis revealed elevated EMT signaling as one 
of the most significantly upregulated gene sets in siPC cells under normal serine and glycine 
concentrations compared to restricted conditions. This upregulation in siPC cells when serine 
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and glycine are present indicates that BC cells may utilize extracellular serine and glycine to 
support EMT signaling and subsequent dissemination of cells from a primary tumor to distant 
sites. Subsequently, an upregulation with baseline amino acid levels may suggest that restriction 
of serine and glycine will reduce EMT signaling and thus suppress proliferative and migratory 
capabilities of these cancer cells. While no research has yet to examine the role of serine and 
glycine restriction on reducing EMT signaling mechanisms, some studies have connected 
impaired glutamine metabolism to decreased EMT-mediated growth factors in BC, particularly 
TGF-𝛽130.  Considering the important substrate role of glutamine and subsequent glutamate in 
the transamination reaction of 3-phosphohydroxypyruvate to 3-phosphoserine for downstream 
serine and glycine biosynthesis, one may conclude that impaired serine and glycine metabolism 
may also impact EMT-mediated growth factors.  
In addition to EMT pathways, our GSEA analysis revealed upregulated inflammatory 
responses and TNF-𝛼 signaling as supportive regulators of the serine and glycine effect. 
Inflammation is not only a byproduct of obesity and high fat conditions, but has demonstrated a 
direct contribution to tumor proliferation, angiogenesis, metastasis, and even resistance to 
chemotherapy131. Surprisingly, epidemiological and clinical studies have shown that 
approximately 25% of all human cancers result from chronic inflammation132. Moreover, 
obesity-associated adipocytes are known to secrete pro-inflammatory cytokines, chemokines and 
growth factors which are linked to the progression of BC133. One of these cytokines, TNF-𝛼, has 
been shown to enhance the invasive ability of tumor cells by stimulating the expression of Snai1 
and Twist and inducing downstream EMT131,134. Expression of TNF-𝛼-induced Snai1 and EMT 
has also been shown to increase the invasiveness of non-metastatic BC cell lines, including 
MCF7 and T47D cells, illustrating the critical role of TNF-𝛼 in mediating inflammation and 
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subsequent invasion of BC cells131. Our findings therefore highlight the influence of serine and 
glycine on TNF-𝛼 and inflammatory directed responses in BC cell migration and metastasis. 
Importantly, the upregulation of inflammatory responses and TNF-𝛼 was observed in both siScr 
and siPC cells, indicating that this serine and glycine effect is not necessarily influenced by the 
loss of PC, but is consistent across BC cells. The upregulation of these signaling pathways 
suggests that serine and glycine may play an important role in stimulating inflammatory-driven 
metastasis. Restriction of serine and glycine may therefore present a potential therapeutic 
strategy for reducing inflammation-driven metastatic spread in BC cells.  
Interferon-𝛼 and interferon-𝛾 were also identified as Hallmark gene sets driving the 
serine and glycine effect in siPC cells. It has been previously established that activation of 
interferon-I pathways (including interferon-𝛼 and interferon-𝛾) increases progression and 
migration of BC cells115. Additionally, recent data suggests that interferon-𝛼 in particular is 
upregulated in inflammatory BCs, characterized by their high rates of metastasis and resistance 
to systemic chemotherapy. Activation of the interferon-𝛼 signaling cascade in this BC subtype 
has been shown to alter immune and stromal cells within the tumor microenvironment thereby 
stimulating an increase in migration135. Thus, the upregulation of these cytokine networks in our 
siPC cells further supports the claim that serine and glycine support proliferation and 
invasiveness.  
Finally, E2F targets, and G2M, were also Hallmark gene sets upregulated in siScr and 
siPC cells. E2Fs are transcription factors that control expression of target genes involved in 
angiogenesis, remodeling of the ECM, BC tumor cell survival, and metastasis to the lungs. 
Investigating these target genes further, scientists have identified that loss of E2F transcription 
factors decreases vascular endothelial growth factor a (VEGFa), and other genes involved in the 
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metastatic potential of BC cells, thus characterizing E2F as a master regulator of pro-metastatic 
genes136,137. G2M, a cell cycle pathway, has also been implicated as a biomarker of metastasis in 
BC subtypes, particularly TNBCs. Elevation of the G2M pathway, as seen in our GSEA analysis, 
has recently been correlated with enriched expression of proliferation-related gene sets as well as 
aggressive phenotypes of tumors and poor survival outcomes138. The upregulation of both E2F 
and G2M signaling pathways in our siScr and siPC cells supports the claim that serine and 
glycine drive increased rates of metastasis in BC cells.  
Taken together, our in vitro findings indicate that loss of PC does not directly promote 
sensitivity to restriction of extracellular serine and glycine. Alternatively, induction of PC may be 
an important biochemical response to limiting NEAA in cancer cells.  Restriction of serine and 
glycine may also target some of the many prognostic biomarkers of metastasis that are upregulated 
under normal amino acid levels, including EMT signaling, inflammatory responses, and cytokine 
production. Further examination of these signaling pathways in serine and glycine restricted 
conditions may provide insight into the direct mechanisms responsible for the observed in vitro 


















CHAPTER 4: GLUTAMINE INHIBITION IMPAIRS CELL GROWTH AND 
MIGRATION  
Background 
In addition to serine and glycine, glutamine has also been established as a critical amino 
acid for proliferating tumor cells. Glutamine metabolism, and downstream glutamate production, 
have multiple functions in cancer cells, including fueling the TCA cycle for energy production, 
supporting nucleotide and fatty acid biosynthesis, and maintaining redox balance139. Glutamine 
can therefore support the building blocks for biosynthesis and biomass accumulation in 
proliferating cancer cells140. Furthermore, glutamine metabolism is transcriptionally regulated by 
Myc and p53 genes, thereby allowing cancer cells to meet energy and redox homeostatic needs 
by increasing the demands of glutamine metabolism141,142. Glutamine is converted to glutamate 
via the enzyme glutaminase (GLS) for downstream 𝛼-ketoglutarate or glutathione synthesis139. 
Suppression of glutaminolysis by GLS inhibition, has shown potent depletion of TCA cycle 
intermediates and increased oxidative stress, thereby impairing cell growth143. Given the energy 
generating and biosynthetic roles of glutamate in proliferative cells, inhibition of GLS may 
provide a potential therapeutic strategy for restricting cancer growth. Indeed, genetic inhibition 
of GLS via shGLS1 prevents Wnt and Snail-induced EMT signaling in MCF-7 BC cells144. 
These results have been further replicated with metabolic inhibitors such as DON and 
BPTES144,145. Additionally, GLS inhibition reduces metastatic outgrowth of osteosarcoma 
tumors in vivo, indicating a potential role of glutamine, and subsequently glutamate, in driving 
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metastatic spread146. Limited research, however, has been conducted on the metastatic role of 
glutamine in BC cell lines, highlighting the need for research in this field.  
Evaluating the role of glutamine in cancer growth and proliferation is incomplete without 
assessing the competitive relationship between glutamine and PC-derived anaplerotic 
metabolism. Glutamine may be the preferred anaplerotic precursor in some proliferative cell 
lines, with one study identifying glutamine as the main contributor to 90% of the oxaloacetate 
pool in glioblastoma cells140. This study also revealed an inverse relationship between glutamine 
levels and PC activity. The preference for glutamine in these cells was correlated with a 
reduction in PC activity, suggesting that cancer cells may rely more heavily on one anaplerotic 
mechanism for growth mechanisms, suppressing the need for the other. On the other hand, 
KRAS-driven lung tumors in mice favor glucose-derived pyruvate and PC for anaplerosis over 
glutamine, again indicating potential tumor-specific tendencies147,148.  
This complex interplay between glutamine and PC may be further explained by the 
metabolic flux that occurs when GLS is inhibited149,150. Metabolic profiling following GLS 
inhibition reveals a shift from glutamine to PC-catalyzed anaplerotic mechanisms in certain cancer 
cells149. Additionally, a number of studies have demonstrated that glutaminase inhibition can be 
directly rescued by alternative metabolic pathways, including glycolysis and fatty acid 
oxidation151,152. These cells therefore demonstrate an ability to compensate for the decrease in 
glutamine-driven anaplerosis by shifting toward glucose-derived pyruvate. Interestingly, studies 
have investigated glioblastoma cells with high PC activity, and found that these cells exhibit 
resistance to the typical growth suppression stimulated by GLS inhibition. When PC is silenced, 
however, glioblastoma cells experience significantly reduced growth149. Additional clinical studies 
have investigated the anti-proliferative role of GLS inhibition, particularly with the orally available 
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GLS inhibitor CB-839, which has shown promising management of advanced metastatic TNBC 
in phase I and phase II clinical trials153.  Efficacy of CB-839 on TNBC growth inhibition, however, 
was strongly impaired by high levels of exogenous pyruvate152. In this model, pyruvate served 
both an anaplerotic role to support fumarate levels in CB-839 treated conditions, as well as a 
paracrine role to decrease the sensitivity of nearby cells to GLS inhibition. Suppression of 
pyruvate, however, antagonized this paracrine effect and increased the growth inhibition activity 
of CB-839152. These results were replicated with BPTES treatment, and demonstrate the important 
metabolic flux of BC cells towards glucose-derived pyruvate and PC-mediated anaplerotic 
mechanisms to support growth when glutamine and glutamate are limited. It can therefore be 
postulated that PC-mediated anaplerosis is essential for the growth of cancer cells under low-
glutamine conditions. We hypothesized that loss of PC, in combination with GLS inhibition via 
the selective inhibitor BPTES, will reduce migration of metM-WntLung BC cells in vitro to a greater 
extent than BPTES or PC suppression alone. 
Results 
Glutamine inhibition increased PC expression  
 To confirm successful PC knockdown in our cell lines, as well as changes in expression 
of PC and PHGDH following GLS inhibition, metM-WntLung shScr and shPC cells were first 
seeded for 24 hours with 1𝜇g/mL doxycycline to induce PC suppression of the shRNA 
constructs. After seeding, cells were treated in the presence or absence of 4𝜇M BPTES for an 
additional 24 hours, then RNA was isolated, cDNA was synthesized, and qPCR was performed 
with PC and PHGDH primer sequences. We identified successful PC knockdown in our shPC 
cells compared to shScr controls under normal media conditions using a 2-way ANOVA to 
validate PC knockdown separately from BPTES interactions (Fig. 7A p=0.0033). In concurrence 
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with the current literature, GLS inhibition via BPTES significantly increased PC expression in 
the shScr cells (p<0.0001), shifting toward a glucose-derived pyruvate anaplerotic mechanism. 
No difference was observed in PC expression when GLS was inhibited in the shPC cells.  
Interestingly, despite the role of glutamate as a nitrogen donor for the serine biosynthesis 
pathway, the relative expression of PHGDH was unchanged between BPTES and normal 
conditions in both shScr and shPC cells (Fig. 7B). This data may suggest an additional 
compensatory mechanism for generating TCA cycle intermediates in BC cells when both GLS 
and PC are inhibited.  
                                   
      
 
Figure 7: Glutamine inhibition via BPTES treatment increased expression of PC in shScr 
metM-WntLung cells. shScr and shPC metM-WntLung cells were treated with or without 4𝜇M 
BPTES for 24 hours. Relative mRNA expression of PC (A) and PHGDH (B) were assessed. A 2-
way ANOVA was conducted to assess the reduction of PC expression in shPC metM-WntLung 
cells. Data are the mean of 5 biological replicates and error bars represent s.e.m. Letters denote 






   
 43 
Glutaminase inhibition decreased cell growth and viability of BC cells 
 To assess the impact of GLS inhibition on cell growth in vitro, shScr cells were seeded in 
a 96-well plate for 24 hours with 1mg/mL doxycycline, then cultured with 4𝜇M BPTES for an 
additional 24 hours. Cell viability following treatment was assessed with an MTT assay. shPC 
cells were also seeded with 1𝜇g/mL doxycycline for 24 hours, then cultured with 4𝜇M BPTES for 
an additional 24 hours to determine the effect of PC loss in combination with GLS inhibition on 
cell growth. No difference in cell viability was observed between shScr and shPC cells under 
control conditions; however, a significant reduction in cell growth was observed in both shScr and 
shPC cells with BPTES treatment (Fig. 8 shScr p=0.0345, shPC p=0.0015). Furthermore, no 
significant changes were noted between shScr and shPC cells with BPTES treatment, suggesting 
that the growth-inhibition observed in these BC cells is driven by BPTES rather than PC. 
 
   
 
Figure 8: Glutamine inhibition via BPTES treatment reduced cell viability of shScr and shPC 
metM-WntLung cells. shScr and shPC metM-WntLung cells were treated in the presence or absence 
of 4𝜇M BPTES for 24 hours and cell viability was assessed using an MTT assay. Data are the 
mean of 5 biological replicates and error bars represent s.e.m. Letters denote significant 
comparisons between conditions. 
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Glutaminase inhibition significantly reduced migration in BC cells 
 In addition to assessing the cell growth and viability of shScr and shPC cells, migratory 
capacity was also analyzed under normal and GLS inhibited conditions. shScr and shPC cells were 
seeded in migration chambers with 1𝜇g/mL doxycycline for 24 hours. Following seeding, the 
chambers were lifted and normal RPMI media, or media supplemented with 4𝜇M BPTES were 
added to each well for an additional 24 hours. Images were taken at time of media treatment and 
at the 24 hour endpoint to assess percent wound closure in each condition. A significant reduction 
in migration was observed in both shScr and shPC cells after BPTES treatment compared to 
control, suggesting that GLS inhibition was sufficient to reduce the migratory capacity of BC cells 
(Fig. 9 shScr p=0.0054, shPC p=0.0182). No difference was observed, however, between shScr 
and shPC cells under BPTES treatment, again indicating that the effect observed in vitro is driven 
by GLS inhibition rather than loss of PC.  
  
Figure 9: Glutamine inhibition via BPTES treatment reduced migratory capacity of shPC 
metM-WntLung cells. shScr and shPC metM-WntLung cells were treated in the presence or absence 
of 4𝜇M BPTES for 24 hours following seeding in migration chambers. Percent wound closure of 
each cell wall was imaged and quantified using the ImageJ MRI wound healing plugin. Data are 
the mean of 5 biological replicates and error bars represent s.e.m. Letters denote significant 
comparisons between conditions. 
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Discussion 
The current understanding of metabolic reprogramming in cancer cells suggests a shift 
from glutamine-mediated anaplerosis to PC-mediated anaplerosis when glutaminolysis is 
inhibited149,150. Having previously demonstrated that serine and glycine restriction, but not PC loss, 
reduces cell growth and migration of BC cells in vitro, we next assessed whether a similar, or 
greater effect is observed when glutamate production from glutamine is inhibited. Furthermore, 
we assayed whether PC, independently of glutamate, is required for cell growth and migration in 
BC cells, as previously seen in the literature in glioblastoma cells149. We therefore utilized the 
selective GLS inhibitor, BPTES with our shScr and shPC cells to test the role of glutamate and PC 
separately, and in combination, on BC growth and migration.  
Our findings reveal similar trends to the data observed with serine and glycine restriction, 
where constriction of available NEAAs such as glutamate, serine, and glycine induces PC 
expression. Of note, BPTES treatment, and subsequent GLS inhibition, significantly increased the 
expression of PC in shScr cells. These results, in accordance with the literature, demonstrate a shift 
toward glycolysis and PC-mediated anaplerosis when glutaminolysis is restricted149. Thus, PC-
mediated anaplerosis may support 𝛼-ketoglutarate production as a precursor for glutamate 
synthesis when GLS is inhibited. Increased demand for glutamate synthesis via 𝛼-ketoglutarate 
may therefore drive the elevated PC expression levels observed in Figure 7. This explanation is 
further supported by the work of Lapidot, et. al., where NMR analysis revealed an association 
between increased metabolic flux through PC under hyperammonemic conditions and stimulation 
of de novo glutamine synthesis in the brains of animal models154. Additional work by Gamberino, 
et al., concluded that PC is not only associated with increased glutamine synthesis, but is required 
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for de novo synthesis of both glutamine and glutamate in astrocytes155. Little research, however, 
has been conducted on assessing this link in BC cells.  
While PC expression levels were increased in shScr cells, PHGDH expression levels were 
not significantly different between BPTES treatment conditions in shScr and shPC cells. This 
finding contradicts current literature where glutamine withdrawal has been shown to induce the 
upregulation of both PHGDH and the downstream transamination enzyme phosphoserine 
aminotransferase (PSAT) in leukemia cells156. These differences, however, may be a result of 
comparing different cancer cell lines. Furthermore, our data may be a result of inadequate GLS 
inhibition by BPTES. While BPTES is reasonably potent in vitro, concentrations of up to 20𝜇M 
may be required to produce a noticeable effect on GLS157. Indeed, while 4𝜇M of BPTES-induced 
suppression of cell viability was statistically significant in our cells, ~70% of viability remained, 
suggesting that a higher dose may be required for greater efficacy. Given this limitation, PHGDH’s 
relationship to PSAT must also be considered. Situated downstream from PHGDH, PSAT’s 
requirement for glutamate occurs after PHGDH activity is complete. It is therefore plausible that 
partial inhibition of GLS may not be sufficient to directly impact PHGDH expression, thereby 
contributing to the lack of differences observed in vitro.  
Finally, we assessed the impact of GLS inhibition on BC cell growth and migration using 
cell viability and wound healing assays. Here we demonstrated a significant reduction in both cell 
proliferation and migration of our shScr and shPC cells compared to untreated control conditions. 
This reduction indicates a GLS-mediated effect on cell growth and metastasis, as has been 
previously demonstrated in the literature with E0771 BC cells158.  Interestingly, no difference in 
proliferation or migration between the shScr and shPC cells was observed, suggesting that this 
response was purely mediated by GLS inhibition, rather than loss of PC. Despite the literature 
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highlighting the potent anti-tumorigenic role of PC inhibition on cancer cells, these findings are in 
agreement with our serine and glycine data suggesting that loss of PC alone is insufficient for 
inhibiting cell growth and migration in our cell lines in vitro. Thus, a major limitation of this study 
may be identified in our PC knockdown methods. Although we were able to successfully suppress 
PC expression in both siPC and shPC constructs, future experiments should be optimized for 
greater PC reduction prior to experimentation.  
 In conclusion, we demonstrated that GLS inhibition via BPTES treatment significantly 
increases PC expression levels, and subsequently impairs cell growth and migration of BC cells 
in vitro. GLS inhibition may therefore increase metabolic dependence on PC-mediated 
anaplerosis for glutamate synthesis and subsequent one-carbon metabolism in BC cells. Loss of 
PC in this model, however, did not directly influence proliferation or metastasis rates, indicating 


















CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS 
Redox Defense in Lung Colonization 
This study highlights the importance of PC in mediating mechanisms involved in BC 
growth and migration. More specifically, we identified an increased reliance of BC cells on PC 
expression for energy production and cell survival following restriction of extracellular serine and 
glycine. This restriction also demonstrated suppression of multiple target mechanisms within the 
metastatic cascade. We concluded that reduction of PC may not directly promote sensitivity of BC 
cells to loss of extracellular serine and glycine. Furthermore, we demonstrated that glutamate 
restriction via GLS inhibition supports a metabolic shift toward PC-mediated anaplerosis. This 
work with amino acid metabolism therefore positions PC as an adaptive mechanism to the 
disruption of various reduced nitrogen sources. 
Importantly, both serine and glycine metabolism, and glutamine and glutamate metabolism 
have been implicated in supporting redox defense mechanisms. As NEAAs, serine, glycine, and 
glutamate are all precursors for glutathione synthesis, which is critical to ROS defense159. The 
conversion of glutamine to glutamate via GLS supports NADPH production, a required electron 
donor for maintaining glutathione in its reduced state91. In addition, serine and glycine directly 
contribute to the one-carbon metabolism pool, another source of NADPH production and 
glutathione biosynthesis, thereby increasing cellular antioxidant capacity160–162. Although 
increased ROS levels have been established as a hallmark of tumorigenesis and metastasis to 
sustain proliferation and facilitate extravasation, a contrasting role has been identified during 
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tumor cell metastatic colonization159,163. After release from the primary tumor, cancer cells enter 
circulation where they encounter both nitrosative and oxidative stresses elicited by the vascular 
endothelium and immune cells164. These stresses include high levels of cytotoxic ROS and low 
levels of antioxidant enzymes165. These tumor cells must therefore increase redox defense to 
combat increased ROS levels as they colonize to distant organs, particularly in the lungs164. One 
way in which tumor cells may achieve this, specifically in lung colonization, is by increasing the 
activation of HIF-1, an important modulator of metabolic reprogramming166. It can therefore be 
postulated that metastatic colonization to the lungs requires an increase in mechanisms involving 
NEAAs for glutathione synthesis. Our work with serine, glycine, and glutamine restriction may 
therefore provide important insight into this mechanism, and offer a possible therapeutic approach 
for inhibiting metastatic colonization of BC cells to the lungs.  
Surgical Tumor Resection  
These redox defense mechanisms may also prove important in a new phenomenon surrounding 
tumor resection-induced metastatic spread. Surgical tumor resection is a technique used for cancer 
treatment, and in most cases, successfully alleviates patient symptoms167. Although these techniques 
are effective, recurrence, particularly in BC, is frequent168. One study even reports increased local or 
distant recurrence in 31% of patients during the first 4 years post-surgery169. In fact, there is increasing 
evidence, that the invasive surgical techniques performed during tumor resections may actually induce 
metastatic spread167. This phenomenon may be explained by surgery-induced stress which drives a 
systemic effect, inducing inflammation, elevating ROS levels, increasing cytokine release, and 
ultimately elevating cancer recurrence risk167. An additional explanation focuses on the surgery-
induced awakening of dormant tumor cells. Dormant cells are clinically undetectable tumor cells in 
low numbers that can easily evade treatment and survive in circulation170. Over time, however, these 
dormant tumor cells can adapt and colonize at distant organs, contributing to the relapse and metastatic 
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progression of a patient’s cancer171. Tumor resection surgeries have been found to trigger the outgrowth 
of these dormant tumor cells by stimulating a wound-healing, and subsequent inflammatory 
response172.  
Potential targets for surgery-induced metastatic outgrowth have been suggested, including 
perioperative treatment with anti-inflammatory drugs and beta-adrenergic blocking agents, although 
many of the results are inconclusive173,174. Given the role of serine, glycine, and glutamine in redox 
defense, restriction of these NEAAs may offer another target for reducing metastatic outgrowth. 
Additional targets as adjuvant treatment options have also been identified. Given its pro-growth and 
pro-metastatic potential, PC has been implicated as one such target for suppressing recurrence and 
distant metastasis after tumor removal122.  The small molecule compound ZY-444 was recently 
identified as a PC inhibitor, binding to the enzyme and inactivating its catalytic activity175. In a 4T1 
BC tumor model, ZY-444 treatment demonstrated increased survival rates and decreased metastasis 
following tumor resection. The authors concluded that ZY-444 and subsequent PC inhibition may 
provide an important adjuvant treatment option for suppressing surgery-induced recurrence in mouse 
models175. Ongoing work in our lab will therefore utilize an in vivo model of tumor resection surgeries 
in combination with PC inhibition to assess the colonization of BC cells to the lungs under low PC 
enzymatic activity.  
Animal Design Protocol 
Future directions for this study will include obtaining 60 8-9 week old female C57Bl/6 mice 
for a tumor resection surgery. Mice will be placed on a control diet ad libitum to acclimate (10% kcal 
from fat, Research Diets D12450J). After one week of acclimation, mice will be randomized to receive 
an injection of either metM-WntLung mammary cancer cells with doxycycline-inducible PC knockdown 
(shPC, n=30), or metM-WntLung cells with a doxycycline-inducible scramble control (shScr, n=30). 
1x106 cells will be orthotopically injected into the 4th mammary fat pad of each mouse. Previous 
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experiments have shown this number of cells to produce easily resectable tumor sized between 350-
500mm3 after approximately one week176. All mice will then be given an additional 250ug/mL 
doxycycline added to their water source to induce shPC constructs.  Mice will be palpated twice weekly 
and imaged weekly via IVIS in vivo bioluminescent imaging to monitor tumor growth. Tumors will be 
resected once size reaches 350-500mm3.  
 
 
Figure 10: Tumor resection mouse study design 
 
Tumor Resection Surgeries 
Once tumors reach 350-500mm3, resection surgeries will be performed using aseptic 
techniques. Mice will be anesthetized using 5% isoflurane in O2 then maintained at a rate of 1.5-2% 
isoflurane in O2 during surgery. A ~1cm incision will be made adjacent to the tumor to be resected. 
The tumor will then be dissected from the skin layer and body wall using sterile blunt scissors. 
Following resection, tumors will be placed in liquid nitrogen for future analysis. The incision site will 
then be closed and mice will receive a subcutaneous injection of 5mg/kg Carprofen at the incision site 
intraoperatively. Mice will be monitored daily and sutures will be removed after healing has occurred 
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or after 10 days post-surgery have elapsed. Any recurrence and subsequent metastases development 
will be evaluated and tracked in the following weeks. 
Ex Vivo Tumor Analysis 
 Mouse weights and tumor size will be measured weekly prior to surgery to determine any 
differences in tumor growth between control and PC knockdown conditions. Upon completion of 
surgeries, we will analyze several key aspects of the resected tumors. We will first measure and 
weigh the tumors ex vivo immediately following resection to assess differences in tumor volume 
between shScr and shPC metM-WntLung tumors. To closely model in vivo tumor characteristics and 
microenvironments, while validating our in vitro experimentation, ex vivo tumors will be dissected 
and cultured in a laboratory environment. qPCR techniques will be performed to determined 
possible differences in PC and PHGDH expression levels between tumor types. A Western 




























CHAPTER 6: CONCLUSIONS 
 
This study aimed to assess the combined effects of PC inhibition and associated 
metabolic alterations on restricting BC growth and migration. It was hypothesized that loss of PC 
would sensitize BC cells to loss of extracellular serine and glycine, thereby stimulating potent 
growth-inhibition mechanisms. Following experimentation, it was determined that loss of PC 
may be an important biochemical response to NEAA restriction in BC cells, but may not directly 
promote sensitivity to the restriction of serine and glycine. A significant suppression of in vitro 
paralogs of metastasis was also observed in cells lacking extracellular serine and glycine, 
indicating that restriction of these NEAA may directly target mechanisms of the metastatic 
cascade.  
The impact of glutamine and glutamate availability, in combination with PC loss, on BC 
growth and migration was also evaluated. Findings indicate that GLS inhibition drives a 
metabolic shift toward PC-mediated anaplerosis, but that inhibition of growth and migration 
responses were mainly influenced by lack of glutamate availability, not loss of PC. Our findings, 
however, may not fully capture the combined effects of serine and glycine restriction or GLS 
inhibition with PC loss due to insufficient PC knockdown constructs. Future experiments are 
directed at reassessing PC knockdown in mouse models and determining whether the responses 
observed in vitro are replicated in vivo via tumor resection surgeries. Taken together, this study 
therefore provides evidence that targeting metabolic reprogramming mechanisms, particularly 
through serine and glycine restriction or GLS inhibition in combination with PC loss, may 
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provide important therapeutic options for reducing proliferation and migration of metastasizing 
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